PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35260678-7 2022 The interaction between febuxostat treatment and presence of proteinuria in terms of eGFR slope was significant (P for interaction = 0.019). Febuxostat 24-34 epidermal growth factor receptor Homo sapiens 85-89 28302902-12 2017 Among the evaluated predictors, multivariate analysis showed that only the lowest eGFR tertile was significantly associated with myopathy in febuxostat users. Febuxostat 141-151 epidermal growth factor receptor Homo sapiens 82-86 28302902-15 2017 CONCLUSIONS: Patients with severely reduced eGFR had higher risk of myopathy with treatment of febuxostat. Febuxostat 95-105 epidermal growth factor receptor Homo sapiens 44-48 24152124-7 2014 The change from baseline in eGFR was positive at all time points during febuxostat treatment and the increase of 2.3 (+-5.6) mL/min/1.73 m2 at 6 months was significant (p = 0.0027). Febuxostat 72-82 epidermal growth factor receptor Homo sapiens 28-32 24152124-8 2014 Whereas the eGFR slope was negative during allopurinol treatment, it became positive after the switch to febuxostat. Febuxostat 105-115 epidermal growth factor receptor Homo sapiens 12-16 24152124-9 2014 The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05). Febuxostat 42-52 epidermal growth factor receptor Homo sapiens 14-18 24152124-9 2014 The change in eGFR slope before and after febuxostat treatment was significant for all patients (p < 0.01), for male patients (p < 0.05), and for patients with a baseline eGFR of <15 mL/min/1.73 m2 (p < 0.05). Febuxostat 42-52 epidermal growth factor receptor Homo sapiens 177-181 31335677-10 2019 Also, a significant higher eGFR was found in the febuxostat treated group among CKD stage 3 and 4 patients. Febuxostat 49-59 epidermal growth factor receptor Homo sapiens 27-31 30291473-6 2019 The eGFR in the febuxostat group showed an increase from 28.45 to 30.65 mL/min/1.73 m2 at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39 mL/min/1.73 m2. Febuxostat 16-26 epidermal growth factor receptor Homo sapiens 4-8